Current insights and future perspectives of treatment strategies for biliary tract cancer

doi:10.4251/wjgo.v17.i10.110415

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 10

This Article

(45)

(46)

(0)

(976)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastrointest Oncol. Oct 15, 2025; 17(10): 110415
Published online Oct 15, 2025. doi: 10.4251/wjgo.v17.i10.110415

Table 4 Fibroblast growth factor receptor inhibitors in cholangiocarcinoma

Drug name	Target FGFR	Clinical status (for CCA)	Type
Pemigatinib	FGFR1-3	Approved (United States/European Union/Japan)	Reversible
Infigratinib	FGFR1-3	Withdrawn (formerly approved in United States)	Reversible
Zoligratinib (Debio 1347)	FGFR1-3	Phase 2 ongoing	Reversible
Fexagratinib (AZD4547)	FGFR1-3	Phase 1-2 completed	Reversible
Erdafitinib	FGFR1-4	Approved (bladder CA); exploratory in CCA	Reversible
Derazantinib	FGFR1-3	Phase 2 (FIDES-01)	Reversible
Tasurgratinib (E7090)	FGFR1-3	Approved (Japan); phase 2 completed	Reversible
Futibatinib	FGFR1-4	Approved (United States/Japan)	Irreversible
Lirafugratinib (RLY-4008)	FGFR2 selective	Phase 1/2 with high ORR	Irreversible
PRN1371	FGFR1-4	Early phase trials	Irreversible
H3B-6527	FGFR4 selective	FGFR4 focus (HCC)	Irreversible
Ponatinib	Multitarget (BCR-ABL, FGFR)	Not specific for CCA	Multitarget
Lucitanib	Multitarget (VEGFR, FGFR)	Exploratory	Multitarget
Nintedanib	Multitarget (VEGFR, FGFR, PDGFR)	Exploratory	Multitarget

FGFR: Fibroblast growth factor receptor; VEGFR: Vascular endothelial growth factor receptor; BCR-ABL: Breakpoint cluster region-Abelson; PDGFR: Platelet-derived growth factor receptor; CA: Cancer; CCA: Cholangiocarcinoma; ORR: Objective response rate; HCC: Hepatocellular carcinoma.

Full Size Table

Citation: Nakagawa K, Tsujinaka S, Katayose Y, Yambe K, Sakurai H, Takami K, Kondo N, Yamamoto K, Shibata C. Current insights and future perspectives of treatment strategies for biliary tract cancer. World J Gastrointest Oncol 2025; 17(10): 110415
URL: https://www.wjgnet.com/1948-5204/full/v17/i10/110415.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i10.110415

Nakagawa K, Tsujinaka S, Katayose Y, Yambe K, Sakurai H, Takami K, Kondo N, Yamamoto K, Shibata C. Current insights and future perspectives of treatment strategies for biliary tract cancer. World J Gastrointest Oncol 2025; 17(10): 110415 [PMID: 41114096 DOI: 10.4251/wjgo.v17.i10.110415]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.